AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6991196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 20
Study 6991196 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 6991196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31300051 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First model (immediate access to scattered site housing and mental health support services)
Number of subjects: 575
Study 31300051 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 575
Study 31300051 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First model
Number of subjects: 575
Study 28179255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) + l-NAME
Number of subjects: 14
Study 28179255 — intervention group
Group type: COMPARATOR
Intervention: Losartan (LOS) + l-NAME
Number of subjects: 14
Study 28179255 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine (MANI) + l-NAME
Number of subjects: 14
Study 25592198 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA)
Number of subjects: 539
Study 25592198 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Number of subjects: 539
Study 25592198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 539
Study 23919898 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (3-12 mg/day)
Number of subjects: 42
Study 23919898 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10-40 mg/day)
Number of subjects: 42
Study 21481517 — intervention group
Group type: COMPARATOR
Intervention: 2005 guidelines
Number of subjects: 82
Study 21481517 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 ERC guidelines hand position modification
Number of subjects: 82
Study 19036070 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (n = 58)
Number of subjects: 116
Study 17197279 — intervention group
Group type: EXPERIMENTAL
Intervention: $50 bonus for accurate diet recalls on the first two of four recalls
Number of subjects: 0
Study 17197279 — intervention group
Group type: EXPERIMENTAL
Intervention: $50 bonus for the last two recalls
Number of subjects: 0
Study 17197279 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 0
Study 14735129 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (2.5 x seizure threshold) bilateral (BL) ECT
Number of subjects: 54
Study 14735129 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (6 x seizure threshold) RUL ECT
Number of subjects: 54
Study 14735129 — intervention group
Group type: COMPARATOR
Intervention: Low (1.5 x seizure threshold) RUL ECT
Number of subjects: 54
Study 14735129 — intervention group
Group type: COMPARATOR
Intervention: Moderate (2.5 x seizure threshold) RUL ECT
Number of subjects: 54
Study 14735129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral (BL) ECT
Number of subjects: 54
Study 14735129 — intervention group
Group type: COMPARATOR
Intervention: RUL ECT (all doses)
Number of subjects: 54
Study 14735129 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG measures
Number of subjects: 54
Study 11179154 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention with two individual treatment sessions and two telephone follow up calls, supported by a comprehensive educational pack.
Number of subjects: 148
Study 11179154 — intervention group
Group type: COMPARATOR
Intervention: Standardised medical care (control group).
Number of subjects: 148
Study 11179154 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum intervention group (no further treatment).
Number of subjects: 148
Study 11179154 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention group (additional seven follow up calls).
Number of subjects: 148
Study 11179154 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum intervention group (additional seven face to face sessions over four months).
Number of subjects: 148
Study 9756807 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation
Number of subjects: 185
Study 9756807 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 185
Study 8118539 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol treatment (two puffs from a metered-dose inhaler with spacer at 20-minute intervals)
Number of subjects: 42
Study 8118539 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (two puffs from a metered-dose inhaler with spacer at 20-minute intervals)
Number of subjects: 42
Study 3562541 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted belt worn around the pelvis
Number of subjects: 20
Study 3562541 — intervention group
Group type: COMPARATOR
Intervention: No weighted belt (control condition)
Number of subjects: 20
Study 29909782 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic push-through technique
Number of subjects: 56
Study 29909782 — intervention group
Group type: COMPARATOR
Intervention: Microscopic underlay technique
Number of subjects: 56
Study 26777322 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 300
Study 26777322 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 30 mg
Number of subjects: 300
Study 26777322 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg
Number of subjects: 300
Study 26777322 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 300
Study 25702740 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron reduction intervention
Number of subjects: 0
Study 24299257 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical therapy intervention (ePT) consisting primarily of manual therapy, exercise, and modalities.
Number of subjects: 0
Study 24299257 — intervention group
Group type: COMPARATOR
Intervention: Usual podiatric care (uPOD) consisting primarily of a stretching handout, medication, injections, and orthotics.
Number of subjects: 0
Study 24299257 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical therapy intervention (ePT)
Number of subjects: 0
Study 24299257 — intervention group
Group type: COMPARATOR
Intervention: Usual podiatric care (uPOD)
Number of subjects: 0
Study 17072024 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult kayakers
Number of subjects: 76
Study 17072024 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 17072024 — intervention group
Group type: EXPERIMENTAL
Intervention: Young kayakers
Number of subjects: 76
Study 12850362 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B streptococcal type III CPS-TT conjugate vaccine
Number of subjects: 0
Study 12850362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10717782 — intervention group
Group type: EXPERIMENTAL
Intervention: One implant of MENT acetate
Number of subjects: 15
Study 10717782 — intervention group
Group type: EXPERIMENTAL
Intervention: Two implants of MENT acetate
Number of subjects: 15
Study 10717782 — intervention group
Group type: EXPERIMENTAL
Intervention: Four implants of MENT acetate
Number of subjects: 15
Study 7794709 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 17
Study 7794709 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 17
Study 1718693 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (50mg 3 times daily)
Number of subjects: 54
Study 1718693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20mg 3 times daily)
Number of subjects: 54
Study 1718693 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (100mg twice daily)
Number of subjects: 54
Study 1718693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20mg twice daily)
Number of subjects: 54
Study 6152885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve blockades (ICB) with 18-28 ml of plain bupivacaine 0.5% (1.30-1.82 mg kg-1)
Number of subjects: 26
Study 6152885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve blockades (ICB) with bupivacaine
Number of subjects: 26
Study 6152885 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 26
Study 29979283 — intervention group
Group type: COMPARATOR
Intervention: Traditional Straight Set (TS)
Number of subjects: 12
Study 29979283 — intervention group
Group type: EXPERIMENTAL
Intervention: Agonist-Antagonist Paired Set (PS)
Number of subjects: 12
Study 31556793 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint analysis
Number of subjects: 194
Study 31556793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating scale
Number of subjects: 194
Study 31556793 — intervention group
Group type: COMPARATOR
Intervention: Time tradeoff
Number of subjects: 194
Study 28138734 — intervention group
Group type: EXPERIMENTAL
Intervention: IMD enriched with EPA, GLA, and antioxidants
Number of subjects: 87
Study 28138734 — intervention group
Group type: COMPARATOR
Intervention: Standard isocaloric, isonitrogenous diet (control group)
Number of subjects: 87
Study 25956274 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with alfentanyl
Number of subjects: 51
Study 25956274 — intervention group
Group type: COMPARATOR
Intervention: Midazolam with alfentanyl
Number of subjects: 51
Study 23448107 — intervention group
Group type: COMPARATOR
Intervention: Individual Education (IE)
Number of subjects: 623
Study 23448107 — intervention group
Group type: COMPARATOR
Intervention: Group Education (GE)
Number of subjects: 623
Study 23448107 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care (UC)
Number of subjects: 623
Study 21270204 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic fat fraction (PFF) in Hispanics
Number of subjects: 138
Study 21270204 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic fat fraction (PFF) in males
Number of subjects: 138
Study 21270204 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PFF with VAT
Number of subjects: 138
Study 21270204 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PFF with HFF
Number of subjects: 138
Study 21270204 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PFF with FFA
Number of subjects: 138
Study 21270204 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PFF with inflammatory markers
Number of subjects: 138
Study 21270204 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of PFF
Number of subjects: 138
Study 21270204 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PFF with insulin sensitivity and β-cell function
Number of subjects: 138
Study 18029219 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic lumbar support (orthosis)
Number of subjects: 29
Study 18029219 — intervention group
Group type: COMPARATOR
Intervention: Control group (no orthosis)
Number of subjects: 29
Study 16965523 — intervention group
Group type: EXPERIMENTAL
Intervention: Test toothpaste containing 0.24% sodium monofluorophosphate, 0.3% triclosan, and 2% polyvinyl‐methyl ether maleic acid
Number of subjects: 34
Study 16965523 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste containing 0.76% sodium monofluorophosphate and 0.1% sodium fluoride
Number of subjects: 34
Study 14979610 — intervention group
Group type: EXPERIMENTAL
Intervention: MLBL (immunostimulating therapy) - one sublingual tablet per day for 10 consecutive days per month for 3 months
Number of subjects: 47
Study 14979610 — intervention group
Group type: COMPARATOR
Intervention: Placebo - one sublingual tablet of taste masked placebo per day for 10 consecutive days per month for 3 months
Number of subjects: 47
Study 11135021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan, 50 mg
Number of subjects: 249
Study 9291760 — intervention group
Group type: EXPERIMENTAL
Intervention: Portex introducer
Number of subjects: 89
Study 9291760 — intervention group
Group type: COMPARATOR
Intervention: No introducer
Number of subjects: 89
Study 8361862 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic verapamil (one specific generic product)
Number of subjects: 16
Study 8361862 — intervention group
Group type: COMPARATOR
Intervention: Brand-name verapamil
Number of subjects: 16
Study 3089941 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 2 g b.i.d. for ten days
Number of subjects: 20
Study 3089941 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethylpenicillin 2 g b.i.d. and metronidazole 0.8 g b.i.d. for ten days
Number of subjects: 20
Study 29659896 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 2000 mg daily
Number of subjects: 131
Study 29659896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 27106005 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate second resection of the tumor bed after complete TUR (Group I)
Number of subjects: 47
Study 27106005 — intervention group
Group type: COMPARATOR
Intervention: Delayed second TURB (Group II)
Number of subjects: 47
Study 24100619 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-demographic + falls risk factors
Number of subjects: 1088
Study 24100619 — intervention group
Group type: COMPARATOR
Intervention: Socio-demographic + falls risk factors + functional measures
Number of subjects: 1088
Study 24100619 — intervention group
Group type: EXPERIMENTAL
Intervention: Unable to rise from a chair of knee height
Number of subjects: 1088
Study 24100619 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower household income
Number of subjects: 1088
Study 24100619 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a walking aid
Number of subjects: 1088
Study 24100619 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty in using public transport
Number of subjects: 1088
Study 24100619 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorer physical health
Number of subjects: 1088
Study 24100619 — intervention group
Group type: EXPERIMENTAL
Intervention: Black/minority ethnic group
Number of subjects: 1088
Study 24100619 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported balance problems
Number of subjects: 1088
Study 24100619 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational level
Number of subjects: 1088
Study 24100619 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 1088
Study 21375564 — intervention group
Group type: EXPERIMENTAL
Intervention: Information provided to mothers about teething symptoms and management (3 rounds of printed information at enrolment, 6 months, and 12 months)
Number of subjects: 441
Study 21375564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 441
Study 20718183 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.3 g/kg/day for seven days)
Number of subjects: 0
Study 20718183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19150030 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported food allergy prevalence
Number of subjects: 3099
Study 19150030 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen types
Number of subjects: 3099
Study 19150030 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of food allergy
Number of subjects: 3099
Study 19150030 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic diseases association
Number of subjects: 3099
Study 17273676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopsorin 0.05%
Number of subjects: 20
Study 14636103 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate supplementation (30 g/day for the first 2 weeks, 15 g/day for the final 2 weeks)
Number of subjects: 17
Study 14636103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 11276624 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IFN alpha-2b
Number of subjects: 16
Study 11276624 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IFN alpha-2b
Number of subjects: 16
Study 11276624 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 16
Study 8860710 — intervention group
Group type: EXPERIMENTAL
Intervention: Double filtration plasmapheresis (DFPP)
Number of subjects: 5
Study 8860710 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermofiltration (TFPP)
Number of subjects: 5
Study 8860710 — intervention group
Group type: COMPARATOR
Intervention: Low-density lipoprotein adsorptive (PA)
Number of subjects: 5
Study 8860710 — intervention group
Group type: EXPERIMENTAL
Intervention: DFPP and TFPP
Number of subjects: 5
Study 8860710 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods (DFPP, TFPP, PA)
Number of subjects: 5
Study 8860710 — intervention group
Group type: EXPERIMENTAL
Intervention: DFPP
Number of subjects: 5
Study 8860710 — intervention group
Group type: EXPERIMENTAL
Intervention: TFPP and PA
Number of subjects: 5
Study 1520109 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin
Number of subjects: 0
Study 1520109 — intervention group
Group type: COMPARATOR
Intervention: 0.3% tobramycin
Number of subjects: 0
Study 6404192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 12
Study 6404192 — intervention group
Group type: COMPARATOR
Intervention: DSCG (20 mg)
Number of subjects: 12
Study 31774713 — intervention group
Group type: EXPERIMENTAL
Intervention: Health worker breast health training at intervention HCs
Number of subjects: 1792
Study 28768848 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (specific agents not detailed, but includes aspirin-clopidogrel)
Number of subjects: 43112
Study 28768848 — intervention group
Group type: EXPERIMENTAL
Intervention: S 2 TOP-BLEED score
Number of subjects: 43112
Study 28768848 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of S 2 TOP-BLEED score
Number of subjects: 43112
Study 26647104 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling assistance plus self-generated messages
Number of subjects: 24
Study 26647104 — intervention group
Group type: COMPARATOR
Intervention: Self-generated messages only
Number of subjects: 24
Study 25111348 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisource phase-controlled radiofrequency (MPCRF) treatment on the treated side of the face
Number of subjects: 10
Study 25111348 — intervention group
Group type: COMPARATOR
Intervention: Untreated side of the face (control)
Number of subjects: 10
Study 22514257 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 90
Study 22514257 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 90
Study 22514257 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 19410683 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 10001
Study 19410683 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d
Number of subjects: 10001
Study 17908280 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy arm (biopsies at 0, 1, 2, 3, and 6 months)
Number of subjects: 240
Study 17908280 — intervention group
Group type: COMPARATOR
Intervention: Control arm (biopsies at 0 and 6 months only)
Number of subjects: 240
Study 17908280 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy arm
Number of subjects: 240
Study 17908280 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 240
Study 15031778 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone 45 mg once daily
Number of subjects: 0
Study 15031778 — intervention group
Group type: COMPARATOR
Intervention: acarbose 300 mg/day (3 equal doses)
Number of subjects: 0
Study 11812672 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Protection Study
Number of subjects: 0
Study 11812672 — intervention group
Group type: EXPERIMENTAL
Intervention: IONA
Number of subjects: 0
Study 11812672 — intervention group
Group type: EXPERIMENTAL
Intervention: CARISA
Number of subjects: 0
Study 11812672 — intervention group
Group type: EXPERIMENTAL
Intervention: ENRICHD
Number of subjects: 0
Study 11812672 — intervention group
Group type: EXPERIMENTAL
Intervention: ACUTE
Number of subjects: 0
Study 11812672 — intervention group
Group type: EXPERIMENTAL
Intervention: ALIVE
Number of subjects: 0
Study 11812672 — intervention group
Group type: EXPERIMENTAL
Intervention: MADIT II
Number of subjects: 0
Study 11812672 — intervention group
Group type: EXPERIMENTAL
Intervention: REMATCH
Number of subjects: 0
Study 10450615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 120
Study 10450615 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy (SPT) plus antidepressant medication
Number of subjects: 120
Study 10450615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 10450615 — intervention group
Group type: COMPARATOR
Intervention: Medication-alone condition
Number of subjects: 120
Study 7604152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide 15%
Number of subjects: 12
Study 7604152 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide 0% (placebo)
Number of subjects: 12
Study 7604152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide 3%
Number of subjects: 12
Study 7604152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide 5%
Number of subjects: 12
Study 7604152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide 7%
Number of subjects: 12
Study 7604152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide 10%
Number of subjects: 12
Study 2232453 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) + triamterene
Number of subjects: 79
Study 2232453 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) + amiloride
Number of subjects: 79
Study 2232453 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) alone
Number of subjects: 79
Study 2232453 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) + potassium-sparing diuretics (double doses)
Number of subjects: 79
Study 331107 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous-vein-bypass grafting
Number of subjects: 596
Study 331107 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 596
Study 28349578 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention providing pharmaceutical care services and close collaboration with physicians.
Number of subjects: 104
Study 28349578 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (control group).
Number of subjects: 104